Notice of Proposed Rule by DEA Regarding CSOS

| by: Deneen Fumich, RPh | Article Posted: March 1, 2023 |

On February 2, 2023, the Federal Register included the notice of proposed rulemaking by the DEA for the purpose to amend the regulations to conform to the Controlled Substance Ordering System (CSOS) modernization effort.

In summary as cited within the notice:

“modernization effort by requiring all CSOS enrollment applications and supporting materials to be submitted through the Diversion Control Division secure online portal. These amendments would improve the enrollment process by aligning it with DEA’s current requirements for other online form submissions. The online submission of enrollment applications and supporting material through the secure network application portal would increase the efficiency of the enrollment, modification, and revocation processes, and ensure DEA’s receipt of accurate documentation in a more timely and organized manner.”

Electronic comments must be submitted, and written comments must be postmarked, on or before April 3, 2023. To ensure proper handling of comments, please reference “Docket No. DEA-732” on all correspondence, including any attachments. Comments maybe submitted electronically.

The Drug Enforcement Administration (DEA) encourages that all comments be submitted electronically through the Federal eRulemaking Portal which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments

To receive more articles like this and other industry news, make sure to subscribe to our newsletter by clicking here.

Disclaimer: Pharma Solutions makes every effort to provide accurate information in the content it offers. However, the information provided is “as is” and Pharma Solutions makes no warranties, express or implied, as to the content provided. Pharma Solutions assumes no liability or responsibility for any errors or omissions in the content provided. Laws and regulations that are referenced herein may change over time and as such the content offered is not to be interpreted as advice. Pharma Solutions shall not be liable for any damages whatsoever incurred in connection with the use or performance of this information.